» Authors » Jorg Cammenga

Jorg Cammenga

Explore the profile of Jorg Cammenga including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 59
Citations 1549
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ernst M, Versluis J, Valk P, Bierings M, Tamminga R, Hooimeijer L, et al.
Hemasphere . 2025 Jan; 9(1):e70057. PMID: 39822584
Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM, FPD/AML, -FPD), caused by monoallelic deleterious germline variants, is characterized by bleeding diathesis and predisposition for hematologic malignancies, particularly myelodysplastic syndrome (MDS)...
2.
Baliakas P, Tesi B, Cammenga J, Stray-Pedersen A, Jahnukainen K, Klarskov Andersen M, et al.
Hemasphere . 2024 Aug; 8(8):e145. PMID: 39139355
Increasing recognition of germline variants in patients with hematological malignancies prompted us to provide -specific recommendations for diagnosis, surveillance, and treatment. Causative germline variants in the predispose to the development...
3.
Cammenga J
Exp Hematol . 2024 Apr; 134:104217. PMID: 38649131
SAMD9 and SAMD9L are two interferon-regulated genes located adjacent to each other on chromosome 7q21.2. Germline gain-of-function (GL GOF) mutations in SAMD9/SAMD9L are the genetic cause of MIRAGE syndrome, ataxia-pancytopenia...
4.
Tobiasson M, Pandzic T, Illman J, Nilsson L, Westrom S, Ejerblad E, et al.
J Clin Oncol . 2024 Jan; 42(12):1378-1390. PMID: 38232336
Purpose: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and...
5.
Rundberg Nilsson A, Xian H, Shalapour S, Cammenga J, Karin M
Sci Adv . 2023 Oct; 9(43):eadg5391. PMID: 37889967
Hematopoietic stem cells (HSCs) are tightly controlled to maintain a balance between blood cell production and self-renewal. While inflammation-related signaling is a critical regulator of HSC activity, the underlying mechanisms...
6.
Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, Ghosh S, Oburoglu L, Falques-Costa A, et al.
Blood Adv . 2023 Jul; 7(18):5382-5395. PMID: 37505194
Acute myeloid leukemia (AML) is initiated and propagated by leukemia stem cells (LSCs), a self-renewing population of leukemia cells responsible for therapy resistance. Hence, there is an urgent need to...
7.
Malinski B, Vertemara J, Faustini E, Ladenvall C, Norberg A, Zhang Y, et al.
Hum Mol Genet . 2023 Jul; 32(19):2901-2912. PMID: 37440454
Telomere biology disorders (TBDs) are characterized by short telomeres, premature aging, bone marrow failure and cancer predisposition. Germline mutations in NHP2, encoding for one component of the telomerase cofactor H/ACA...
8.
Rundberg Nilsson A, Xian H, Shalapour S, Cammenga J, Karin M
bioRxiv . 2023 Feb; PMID: 36747722
Inflammatory mediators induce emergency myelopoiesis and cycling of adult hematopoietic stem cells (HSCs) through incompletely understood mechanisms. To suppress the unwanted effects of inflammation and preserve its beneficial outcomes, the...
9.
Nilsson C, Linde F, Hulegardh E, Garelius H, Lazarevic V, Antunovic P, et al.
Haematologica . 2022 Aug; 108(4):1015-1025. PMID: 36005563
Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic...
10.
Engvall M, Karlsson Y, Kuchinskaya E, Jornegren A, Mathot L, Pandzic T, et al.
Leuk Lymphoma . 2022 May; 63(10):2311-2320. PMID: 35533071
Germline pathogenic variants in are associated with familial platelet disorder with predisposition to myeloid malignancies (FPD/MM) with intragenic deletions in accounting for almost 7% of all reported variants. We present...